[1P-0577] PRMT5 is a novel cofactor of Foxp3 and can be a target for tumor immunotherapy

〇Yasuhiro Nagai¹, Mei Q. Ji¹, Yan Xiao¹, Bin Li², Hongtao Zhang¹, Takuya Ohtani³, Mark I. Greene¹ (1.Dept. of Path. and Lab. Med., Univ. of Penn., 2.Key Lab. of Mol. Vir. and Immu., Chi. Acad. of Sci., 3.Penn inst. of Immu., Univ. of Penn.)

Cancer Immunotherapy, regulatory T cells, Post-translational modification